NCT06605365

Cross-linked CMC and Silk Proteins in Eye Disease

Ophthalmic Solution in Drye Eye Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: D&V FARMA srl · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their viscoelastic and hydrating, and wound healing properties. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

Conditions

• Dry Eye Disease (DED)

Interventions

Type	Name	Description
DEVICE	CX-HA and CS	Sterile Isotonic ophthalmic solution

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-09-01
• Completion: 2022-09-01
• First posted: 2024-09-20
• Last updated: 2024-09-20

Locations

1 site across 1 country: Italy